Picture: Transgene

Transgene starts 2021 with a new CEO

Strasbourg-based Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer.

In December the Transgene Board approved the appointment of Hedi Ben Brahim as new Chairman and CEO, effective January 2021. Brahim, member of Transgene’s Board since May 2019, will replace Philippe Archinard, company leader since 2005. Archinard will remain a member of the Board of Transgene, and he will become Executive Vice-President, Technological Innovation and Scientific Partnerships at Institut Mérieux. Brahim comes from there. He was Vice-President for Immunotherapy since September 2018. In this role, he was the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO). Prior to joining the Institut Mérieux, he was General Manager at a subsidiary of Vallourec, a solutions provider to the energy sector. Hedi began his career in the public sector at the Ministry of the Economy, Action and Public Accounts, then at the Ministry of Social Affairs and Health. He is a graduate of the École Polytechnique and the École Nationale Supérieure des Mines de Paris.